双重抗血小板药物治疗 dual anti-platelet therapy
最近的观察结果表明，与使用标准抗血小板药物治疗方案的非DM患者相比，DM中达到的血小板抑制作用不足而导致的。
Recent observations suggest that this may be in part due to inadequate platelet inhibition achieved in DM patients compared to non-DM using standard antiplatelet treatment regimens.
结果表明，GMP - 140对AMI的诊断、病情严重程度的评估都有帮助，并为选用抗血小板药物治疗提供了客观依据。
The results indicate that GMP-140 can be used to help the diagnosis of AMI, to assess the severity of AMI and provide an objective index to administer anti-platelet agents.
最大的变化是抗血小板药物的使用率增加，比如双重抗血小板治疗以及抗凝治疗。
The biggest change has been in the increased use of international therapy and anti-platelet agents as dual anti-platelet therapy, and antithrombotics.
应用推荐